DOTmed September 23, 2024
Telix Pharmaceuticals Limited has plans to acquire RLS Inc. for $230 million. The company’s goal is to expand its North American manufacturing and distributing footprint and establish a next-generation radiometal production network.
Telix plans to use RLS’ 31 licensed radiopharmacies located in major U.S. metropolitan cities to establish a radiometal production and distribution network for therapeutic and diagnostic isotopes. RLS has over 100,000 square feet of licensed expansion space that can be used for this project.
Telix also plans to come up with a clear pathway for deploying its ARTMS QUANTM Irradiation System cyclotron technology. The technology allows for decentralized production of purified radiopharmaceuticals and is compatible with most OEM cyclotrons.
Dr. Christian Behrenbruch, managing director and group CEO of...
Today's Sponsors
Today's Sponsor